Subsidiary Knovea signs exclusive US commercialization pact for two Dual Chamber Vial injectables

Knovea Pharmaceutical, a wholly owned subsidiary, has signed a definitive agreement giving a leading global pharma company exclusive rights to commercialise and distribute two Dual Chamber Vial injectables in the US.

Wed 30 Sep 2026

Target Market Size

US$288 million

Product Type

Two Dual Chamber Vial injectables

Geography

United States

Deal Structure

Exclusive long-term commercialization agreement with milestone payments and profit-sharing from launch

Subsidiary Role

Development, regulatory updates, manufacturing and supply

What was announced

Knovea Pharmaceutical Private Limited, a wholly owned subsidiary of Symbiotec Pharmalab, has entered into a definitive Strategic Commercialization Agreement with a leading global multinational pharmaceutical company. The partner's name is withheld due to confidentiality obligations.

The partner gets exclusive rights under a long-term agreement to commercialise and distribute two injectable products in the United States, both built on Knovea's Dual Chamber Vial (DCV) platform.

Who does what

• Knovea: development, regulatory submissions, manufacturing and supply.
• Partner: commercialization and distribution across the U.S., bringing established market access and commercial scale.

Commercial structure

The collaboration is structured to deliver milestone payments through development, regulatory approval and commercial launch, alongside profit-sharing from launch onwards. The consideration details are not disclosed owing to confidentiality obligations.

Market context given by the company

Together, the two products address a U.S. market estimated at approximately US$288 million. The company states the innovator is currently the only company with a DCV presentation in this market.

What a DCV is

A Dual Chamber Vial keeps a drug and its diluent separate until they are combined at the point of care. The company says this protects the stability of sensitive formulations and simplifies preparation for healthcare professionals, with fewer handling steps and sterility maintained through administration.

Management comment

Managing Director Mr. Anil Satwani called the agreement a defining milestone for Knovea, saying the DCV platform was built as a repeatable engine expected to power a growing portfolio of differentiated complex injectables, and that it opens the door to further collaborations.

About the company

Symbiotec, founded in 1995, is positioned in corticosteroid and steroidal-hormone APIs, serving over 200 customers across more than 40 countries through three verticals — APIs, CDMO services and Complex Injectables — supported by four manufacturing facilities in Madhya Pradesh with USFDA, EU-GMP, WHO-GMP and Japan-PMDA approvals.

How to read it

Revenue is tied to development progress, regulatory approval and eventual launch, so timing and amounts depend on future milestones. The transaction is not a related party transaction.

Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.